HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KRSA
Cyclerion Therapeutics, Inc.
There isn't enough reported data to score KRSA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KRSA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KRSA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KRSA PE Valuation
KRSA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KRSA Forward outlook
There aren't enough analyst estimates for KRSA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over KRSA on earnings, with more consistent year-over-year improvement.
KRSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.36 | -$7.18 |
| Q2 2026 | -$11.27 | -$6.16 |
| Q1 2026 | -$9.17 | -$1.12 |
| Q4 2025 | -$7.77 | +$0.70 |
| Q3 2025 | -$5.18 | +$9.16 |
| Q2 2025 | -$5.11 | -176% |
| Q1 2025 | -$8.05 | -$5.68 |
| Q4 2024 | -$8.47 | +$11.96 |
KRSA lost $12.36 per share over the past year, and its loss has widened in each of the last five quarters.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over KRSA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KRSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1M | -43% |
| Q3 2025 | $875K | +351% |
| Q4 2022 | $608K | +14% |
| Q2 2022 | $306K | -90% |
| Q1 2022 | $711K | +1047% |
| Q4 2021 | $533K | +301% |
| Q3 2021 | $348K | -13% |
| Q2 2021 | $3M | +301% |
KRSA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -82% | -110 points |
| Q3 2025 | -115% | +467 points |
| Q2 2025 | -1798% | N/A |
| Q1 2025 | -1799% | N/A |
| Q4 2024 | 28% | N/A |
| Q3 2024 | -581% | N/A |
| Q4 2022 | -1209% | +1482 points |
| Q2 2022 | -4390% | -3851 points |
KRSA's operating margin was −82% last quarter, down 110 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KRSA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.1M | -$46.8M |
| Q2 2026 | -$1.4M | -$929K |
| Q1 2026 | -$1.2M | -$274K |
| Q4 2025 | -$1.6M | -539% |
| Q3 2025 | -$264K | +$1.5M |
| Q2 2025 | -$503K | +$603K |
| Q1 2025 | -$968K | +$903K |
| Q4 2024 | $360K | +$1.9M |
KRSA has burned cash in almost every quarter: −$51M over the past year, against −$1M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KRSA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KRSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2127% | +12.9M shares |
| 1 year | +2983% | +13.1M shares |
| 3 years | +4049% | +13.2M shares |
| 5 years | +5456% | +13.3M shares |
KRSA has 14M diluted shares, up 2983% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KRSA Net Leverage
KRSA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KRSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 63.2 | Neutral |
KRSA's weekly RSI is 58 (neutral) and its Stochastic is 63 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KRSA PE vs Healthcare Sector
| Metric | KRSA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRSA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KRSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 0.5% below |
| 20 week MA | $28.9 | 8.2% above |
| 50 week MA | $21.1 | 48% above |
| 100 week MA | $20.1 | 55% above |
| 200 week MA | $25.3 | 24% above |
KRSA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KRSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $355.6 | $436.8 | +23% |
| 2021 | $436.8 | $245.0 | -44% |
| 2022 | $245.0 | $76.4 | -69% |
| 2023 | $76.4 | $23.5 | -69% |
| 2024 | $23.5 | $23.1 | -1.5% |
| 2025 | $23.1 | $9.45 | -59% |
| 2026 YTD | $9.45 | $31.3 | +231% |
KRSA has the edge over HIMS on returns for 2026, with the stronger performance.